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Abstract
CELADEN was a randomized placebo-controlled trial of 50 patients with confirmed dengue
fever to evaluate the efficacy and safety of celgosivir (A study registered at ClinicalTrials.
gov, number NCT01619969). Celgosivir was given as a 400 mg loading dose and 200 mg
bid (twice a day) over 5 days. Replication competent virus was measured by plaque assay
and compared to reverse transcription quantitative PCR (qPCR) of viral RNA. Pharmacoki-
netics (PK) correlations with viremia, immunological profiling, next generation sequence
(NGS) analysis and hematological data were evaluated as exploratory endpoints here to
identify possible signals of pharmacological activity. Viremia by plaque assay strongly cor-
related with qPCR during the first four days. Immunological profiling demonstrated a qualita-
tive shift in T helper cell profile during the course of infection. NGS analysis did not reveal
any prominent signature that could be associated with drug treatment; however the phylo-
genetic spread of patients’ isolates underlines the importance of strain variability that may
potentially confound interpretation of dengue drug trials conducted during different out-
breaks and in different countries. Celgosivir rapidly converted to castanospermine (Cast)
with mean peak and trough concentrations of 5727 ng/mL (30.2 μM) and 430 ng/mL
(2.3 μM), respectively and cleared with a half-life of 2.5 (± 0.6) hr. Mean viral log reduction
between day 2 and 4 (VLR2-4) was significantly greater in secondary dengue than primary
dengue (p = 0.002). VLR2-4 did not correlate with drug AUC but showed a trend of greater
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response with increasing Cmin. PK modeling identified dosing regimens predicted to
achieve 2.4 to 4.5 times higher Cmin. than in the CELADEN trial for only 13% to 33%
increase in overall dose. A small, non-statistical trend towards better outcome on platelet
nadir and difference between maximum and minimum hematocrit was observed in celgosi-
vir-treated patients with secondary dengue infection. Optimization of the dosing regimen
and patient stratification may enhance the ability of a clinical trial to demonstrate celgosivir
activity in treating dengue fever based on hematological endpoints. A new clinical trial with
a revised dosing regimen is slated to start in 2016 (NCT02569827). Furthermore celgosivir’s
potential value for treatment of other flaviruses such as Zika virus should be investigated
urgently.
Trial Registration: ClinicalTrials.gov NCT01619969
Author Summary
Dengue virus is currently threatening 40% of the world’s population. An approximately
60% efficacious vaccine has been registered for use in Mexico, Brazil, the Philippines, Para-
guay and El Salvador, but there are no approved antiviral treatments available. We have
shown that celgosivir, an endoplasmic reticulum alpha glucosidase inhibitor, has submi-
cromolar activity against all 4 serotypes of dengue virus (DENV) and also efficacious in
mouse model of infection. The strong preclinical pharmacology motivated the conduct of
an investigator-initiated, Phase 1b randomized, double-blind, placebo-controlled trial of
celgosivir in 50 adult dengue patients. Although the trial did not meet the primary end-
points of lowering viremia or fever, the safety profile of the drug prompted extended
hematological, pharmacokinetic, immunological and viral sequence profiling. Here we
report several non-significant trends of pharmacological effect of celgosivir on platelet
count, hematocrit, and NS1 clearance in secondary dengue patients. In addition, pharma-
cokinetic modeling identified an alternate dosing regimen that is predicted to achieve a
4.5-fold increase in minimum drug concentrations during treatment (Cmin) with only a
modest increase in overall dose. A new Phase 2a clinical trial with an optimized dosing
regimen of celgosivir (ClinicalTrials.gov number NCT02569827) is scheduled to start in
the latter part of 2016.
Introduction
Dengue fever is a mosquito-borne viral illness that is endemic in tropical regions around the
world, with an estimated 96 million cases of dengue illness annually [1]. Dengue is one of 17
neglected tropical diseases that the World Health Organization (WHO) has identified for pri-
ority attention due to its disproportionate impact on global health, with cases reported from
over 100 countries [2]. Singapore maintains an aggressive mosquito control program [3], with
spending by the National Environment Agency approaching US$50 million annually. These
efforts have successfully driven the proportion of households harboring the Aedes mosquito,
the vector for dengue, to historic lows of less than 1%. Yet, in the last decade, the incidence
rates have continued to climb, with the highest rate recorded in 2013 of 404.9 cases per 100,000
with 8 deaths [4].
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Currently, there are no approved drugs for dengue. Vaccine development has been under-
way since the 1970s [5], an extraordinarily challenging effort because immunity to one serotype
does not confer protection against the others. Furthermore, a phenomenon known as anti-
body-dependent enhancement (ADE) posits that antibodies to one serotype from a previous
dengue infection increases the risk of more serious forms of the illness, dengue hemorrhagic
fever (DHF) or dengue shock syndrome (DSS) [6,7]. Indeed, the proportion of DHF among
patients with secondary dengue is much higher than those with primary dengue [8,9]. There-
fore, vaccine development has proceeded under the premise that a vaccine must protect against
all four dengue serotypes; otherwise, potentially more serious outcomes may ensue if the sub-
ject achieves only partial immunity. Sanofi’s tetravalent dengue vaccine CYD-TDV achieved
56% and 65% efficacy in Phase 3 field studies in Southeast Asia and Latin America, respec-
tively. Protection was serotype dependent with protective efficacy for DENV 2 of 35% and 42%
in the two trials [10,11]. In December 2015, a number of countries, namely Mexico, Brazil, and
the Philippines, approved CYD-TDV for use as a dengue vaccine. However, the modest vaccine
efficacy, particularly in patients with no previous history of dengue infection, the higher hospi-
talization rate among vaccinated children younger than 9 years in the third year of follow-up
[12,13], and the extended timeframe required to implement large-scale vaccination programs
underscores a continuing need to discover and develop dengue drugs that can be used along-
side vaccines.
Since 2008, five randomized, controlled trials of dengue drugs have been completed [14–18]
All adopted a strategy of repositioning, or using drugs for which human safety data were
already available from approved drugs or from trials of other clinical indications. Celgosivir, an
inhibitor of alpha-glucosidase, a host enzyme required for proper processing of viral surface
glycoproteins, has been given to hundreds of patients in HIV and HCV trials, but further
pharma-driven development of celgosivir was discontinued because approved drugs for those
indications had better or equivalent efficacy in Phase 2 trials [19,20]. When tested in cell-based
assays and an animal model of dengue infection, celgosivir demonstrated submicromolar activ-
ity and prevented death in mice infected with an otherwise lethal dose of virus [21,22]. The
strong preclinical pharmacology results motivated the conduct of a Phase 1b randomized, dou-
ble-blind, placebo-controlled trial in 50 adult dengue patients (CELADEN, NCT01619969).
Although the trial did not meet the primary endpoints of lowering viremia or fever [17], exami-
nation of data for secondary endpoints, presented here, as well as additional studies using a
mouse model of infection [23] have provided insights for a new Phase 2a clinical trial with an
altered regimen of celgosivir (NCT02569827). The analysis presented here may also be infor-
mative for the design of other drug trials for dengue fever.
Methods
Synthesis of Celgosivir
Celgosivir was synthesized according to US patent 5,017,563 [24] by selective C-acylation of
castanospermine (MedChem 101 LLC). A suspension of castanospermine and bis(tributyl tin)
oxide (1:2 molar ratio) in toluene (30 vol) was refluxed under argon for 3 h. The solution was
cooled down to -17°C, then butyryl chloride (1.8 molar excess) was added dropwise over a 10
min period. The mixture was stirred at room temperature for 2 h. Absolute EtOH was added,
and the mixture was stirred for 30 min, followed by addition of 1.5M HCl/EtOH solution
(2-fold molar ratio to butyryl chloride). The mixture was stirred over night (18 h) at room tem-
perature then for 1 h at +3°C. The precipitate was filtered, washed with hexane, and dried in
vacuo. The compound was recrystallized to obtain a product with> 99% purity by HPLC. Cel-
gosivir was synthesized, purified, capsuled in 100 mg doses, and packaged into blister packs at
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a GMP facility, Dalton Pharma Services (Toronto, Ontario, Canada). USP pregelatinized maize
starch was prepared in identical capsules and blister packs for placebo.
Patient Cohort
Patient samples were obtained from a randomized, double-blind and placebo-controlled
proof-of-concept trial (CELADEN) in Singapore to assess the efficacy and safety of celgosivir
in patients with dengue fever [17]. The Trial Protocol is included here again as S1 Text. The
Consort flowchart showing the CELADEN Trial Profile was published previously [17] and is
included in this manuscript as Fig 1. The inclusion and exclusion criteria for CELADEN Trial
was described previously and is included here as S1 Fig. The Dengue Duo (SD Diagnostics)
point-of-care diagnostic kit was used to screen for dengue infection. It consists of two tests,
one for serum NS1 and the other for dengue immunoglobulins (IgM and IgG). Fifty dengue
patients identified by Dengue Duo Diagnostics and with fever>38°C for less than 48 hr were
randomly assigned (24 to celgosivir, 26 to placebo), of which 14 had DENV-1, 32 had DENV-2
and 4 had DENV-3 infection. The patients were housed in the clinical trial facility at the Sin-
ghealth Investigational Medicine Unit for five days during the acute illness period and returned
to the study center for follow-up examinations on study days 7, 10 and 15. Immunoglobulin M
antibody capture or dengue IgG indirect ELISA (Panbio Diagnostics, Providence RI) were per-
formed on baseline samples to identify primary and secondary infection status as described
previously [17].
Ethics Statement
The study was approved by the Singapore Health Services’s Centralized Institutional Review
Board (CIRB Ref:2012/025/E)—and monitored independently by the Singapore Clinical
Research Institute (SCRI), a publicly funded clinical research organization (CRO) [17]. All sub-
jects between the ages of 21–65 years provided written consent to participate in the inpatient
trial as described in detail in our previous publication [16]. It should be noted that all devia-
tions to the study progress during the trial was provided to the Health Sciences Authority of
Singapore and also to an independent data safety monitoring board. The CELADEN trial was
registered with www.ClinicalTrials.gov, number NCT01619969.
Viremia, Clinical Chemistry and Hematology
The method for determination of viral RNA by quantitative polymerase chain reaction (qPCR)
is described elsewhere [17, 22]. Viral load reduction (VLR) was defined as the difference
between viremia (determined by qPCR) at enrollment and at each study day. The primary end-
point was the mean VLR between study days 2 and 4 inclusive (VLR2-4), which is mathemati-
cally equivalent to the area under the curve (AUC) of the VLR curve between those days
divided by the number of days. A plaque assay was also performed to measure viremia, as
described in [22,25]. The plaque assay measures the number of virus particles capable of pro-
ductive infection, unlike the qPCR assay that measures RNA of all viral particles, regardless of
replication competency. Hematology and clinical chemistry assays were standard assays per-
formed in the clinical diagnostic laboratories of Singapore General Hospital.
ELISA for Dengue IgG
A sandwich-based ELISA assay using DENV-2 protein for capture and goat anti-human anti-
body conjugated with horseradish peroxidase as the detecting antibody. Patient sera and posi-
tive and negative human control sera were diluted 1:100 in serum diluent prepared using PBS
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with 0.5% nonfat dry milk. The plates were developed with tetramethylbenzidine as the sub-
strate [26].
Pharmacokinetics
PK samples were collected prior to the first dose and at 23, 25, 47, 49.5, 71, 74 and 95 hr after
the first dose, representing 4 trough and 3 peak levels. Urine was collected in 12-hr periods, the
volume recorded, and a sample reserved for drug assays. Celgosivir and castanospermine con-
centrations were determined on a LC/MS/MS system (Hewlett Packard 1100 with Applied
Biosystems API 3200 MSMS). N-dodecyl-deoxynojirimycin was the internal standard for cel-
gosivir, and 6,7 dihydroxyswainsonine was the internal standard for castanospermine. The LC
column was a Waters Atlantis HILIC Silica column; the mobile phase consisted of 23% 20 mM
Ammonium acetate pH 5.0 in pump A and 77% acetonitrile in pump B for 7 min then changed
to 60% in pump A for 3.9 min. The LC eluent was connected directly to a Sciex API 3200
Fig 1. Subject disposition for CELADEN study [17].
doi:10.1371/journal.pntd.0004851.g001
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triple-quadrupole MS equipped with electrospray ionizing ion source without splitting. The
quadrupoles were operated with unit resolution in the positive ion multiple reaction monitor-
ing mode. The assay had a lower limit of quantitation (LLoQ) of 10 ng/mL and a linear
response over the range of 10 to 2000 ng/mL.
Concentration-time profiles were analyzed with Phoenix WinNonlin v6.3 using a one-com-
partment model with first-order absorption and elimination (Model 3) and weighting by the
inverse of predicted concentration. Two samples were excluded from PK analysis: one was a
trough sample that had a concentration nearly 5 times higher than the other trough samples
from the same patient. The other was a peak sample that had a concentration more than 10
times lower than the other peak samples from the same patient. Both concentrations were
more than 3 standard deviations from the mean of the other patients’ samples at the same time
point. Body weight, age, sex, and renal clearance were evaluated as covariates. Renal clearance
was estimated from serum creatinine levels, patient demographics, and the Crockcroft-Gault
formula. We performed simulations of several dosing regimens being considered for a follow-
on trial of celgosivir in adult dengue subjects. These were performed with Model 3 using fitted
parameters for the population of patients in the CELADEN trial.
The primary virological endpoint of the trial was the mean virological log reduction between
study days 2 and 4 (VLR2-4). To explore the relationship between VLR2-4 and PK, patients’
exposure (Cmin, Cmax or AUC) was subdivided into 3 quantiles: zero exposure (placebo), low
drug exposure (lower quantile) and high drug exposure (upper quantile), and the distribution
of VLR2-4 in each group was graphed.
Cytokine Multiplex Analysis
Patient plasma samples, drawn at 24, 48, 72 and 120 hr after the first dose, were analyzed for
41 cytokines and chemokines using the Human cytokine panel 1 (Merck Millipore cat no.
MPXHCYTO-60K-14) as per manufacturer’s protocol. Briefly, samples were diluted 1:2.5 with
RPMI + 10% fetal calf serum and loaded onto a Millipore Multiscreen BV 96-well filter plate.
Serial dilutions of cytokine standards were prepared in parallel and added to the plate. Milliplex
Cytokine beads were vortexed for 30 sec. and 25 μl was added to each well with culture super-
natants. Samples were then incubated on a plate shaker at 600 rpm in the dark at room temper-
ature for 2 hr. The plate was applied to a Millipore Multiscreen VacuumManifold, washed
twice with 50μl of assay buffer (PBS, pH7.4, 1% BSA, 0.05% Tween20, 0.05% sodium azide),
and each well resuspended with 75μl assay buffer. Twenty-five μl of biotinylated Anti-Human
Multi-Cytokine Reporter was added to each well. The plate was incubated on a plate shaker at
600rpm in the dark at room temperature for 1.5 hr. Streptavidin-Phycoerythrin was diluted
1:12.5 in assay buffer, and then 25μl was added directly to each well. The plate was again incu-
bated on a plate shaker at 600rpm in the dark at room temperature for 30 minutes. Twenty-
five μl of stop solution (0.2% (v/v) formaldehyde in PBS, pH 7.4) was added to each well and
incubated at room temperature for 5 minutes. The plate was then applied to the vacuum mani-
fold and each well resuspended in 125μl assay buffer and shaken for 1 minute. Assay plates
were read with Flexmap 3D systems (Luminex Corp, Austin, TX, USA). Cytokine concentra-
tions were calculated using Bio-Plex Manager 6.0 software with a 5 parameter curve fitting
algorithm applied for standard curve calculations.
Statistical Evaluation of Viral Correlations and Secondary Endpoints
Correlations between log10 plaque forming units (pfu) and log10 viral RNA copy numbers
measured using qPCR at each day were evaluated by the Pearson correlation coefficient. Fish-
er’s exact test was used to compare the number of negative plaque assays (zero pfu) between
Celgosivir PK/PD in Treatment of Dengue Fever
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celgosivir and placebo groups by day and between primary and secondary dengue. Student’s t-
test for two independent samples was used to compare VLR2-4 between primary and second-
ary dengue. The t-test was also used to compare celgosivir and placebo-treated secondary
dengue patients’ platelet nadirs and differences between the maximum minus the minimum
hematocrit. Covariate dependencies on PK parameters were evaluated by linear regression and
deemed statistically significant if the 95% confidence interval of the slope excluded zero. The
Kruskal-Wallis test was performed to evaluate the relationship between exposure (quantiles of
Cmin, Cmax, and AUC) and VLR2-4. Two-way repeated ANOVAs were used to analyze the
effects of time and treatment on the Luminex analyte concentrations. Graphing and statistical
evaluations were performed with R version 2.15.2, Graphpad Prism v 5.0d or SAS statistical
software.
Whole-Genome Amplification and Next-Generation Sequencing of
DENV Isolates
Next-generation whole-genome sequencing of DENV samples isolated from blood at study
days 1, 2, 3 and 4 was performed as described previously [27, 28]. Viral RNA was extracted
from human sera using the QIAamp Viral RNAMini Kit (Qiagen), and cDNA synthesis for
each serotype was carried out with the Maxima HMinus First Strand cDNA Synthesis Kit
(ThermoFisher Scientific) using serotype-specific primers designed to bind to the 3’ end of the
viral genome. The entire DENV genome was PCR-amplified in 6 overlapping fragments, each
approximately 2 kb in length with the PfuUltra II Fusion HS DNA Polymerase (Agilent Tech-
nologies). Table 1 lists the number of patient samples that were extracted and Table 2 lists the
primer sequences used for the dengue serotypes. PCR products were gel-extracted and purified
using the Qiagen Gel Extraction Kit (Qiagen).
For each sample, equal amounts of all PCR-amplified fragments were combined and
sheared on the Covaris S2 sonicator (Covaris) to achieve a peak size range of 100–300 bp
(shearing conditions: duty cycle—20%; intensity—5; cycles per burst—200; time—110 sec-
onds). Samples were purified with the Qiagen PCR Purification Kit (Qiagen) and their quality
assessed on the Agilent 2100 Bioanalyzer with a DNA 1000 Chip (Agilent Technologies).
Library preparation was performed with the KAPA Library Preparation Kit (KAPA Biosci-
ences). After end-repair, A-tailing, and adapter ligation, ligated products in the 200–400 bp
range were gel-extracted with the Qiagen Gel Extraction Kit (Qiagen). Samples were subjected
to 14 PCR cycles to incorporate multiplexing indices and quantified using the Agilent Bioana-
lyzer. Samples were then diluted to 10 nM and pooled. Paired-end multiplexed sequencing (2 x
76 bp reads) [29] of libraries was performed on the Illumina HiSeq (Illumina) at the Genome
Institute of Singapore.
Mapping and Single Nucleotide Variant (SNV) Calling
FastQC [FastQC: A quality control tool for high throughput sequence data (http://www.
bioinformatics.babraham.ac.uk/projects/fastqc/)] was used to check the quality of the reads
Table 1. Patient sample information.
Serotype Treatment Number of sequences obtained from patients
DENV1 Placebo 4
Celgosivir 6
DENV2 Placebo 17
Celgosivir 8
doi:10.1371/journal.pntd.0004851.t001
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from Illumina-generated FASTQ files. Trim Galore! was used to trim and filter the reads with
minimum quality cutoff of 20 and minimum read length of 35 bp. The consensus genome for
the sample at time point one was generated using the bam2cons_iter.sh script from the Viral
Pipeline Runner (ViPR, available at https://github.com/CSB5/vipr), which uses the Burrows-
Wheeler Aligner to perform iterative mapping of paired-end reads to the reference [29].
DENV genome of samples isolated from later time points was then mapped against the consen-
sus, generated based on the maximum frequency of the nucleotide at a given position, using
BWA-MEM v0.7.5 aligner. Picard Tools v1.95 [30] were used to remove PCR duplicates and
base calibration, and indel realignment was done by GATK v3.3. SNVs for each sample were
detected using LoFreq2 software [31], which incorporates base-call quality scores as error
probabilities into its model to distinguish SNVs from the average sequencing error rate, and
assigns a p-value to each position (Bonferroni-corrected p-value> 0.05). As LoFreq has previ-
ously been applied to DENV datasets, and its SNV predictions on these datasets have been
experimentally validated down to 0.5% allele frequency [27, 32], we filtered the SNPs with a
threshold of coverage of>1000 and allele frequency of>0.5%. SNVs that were located within
primer sequences were discarded. An in-house R script was used to group the samples and
count the number of SNVs occurring at each genomic position. The dN/dS analysis, mutation
density (SNVs per 100 bp) and all statistical tests were also performed in R. For identification
of mutational cold spot, SNVs from groups of samples were pooled and then scanned for win-
dows (minimum size of 40) with a depletion of SNVs (binomial test; Bonferroni corrected p-
value< 0.05).
Phylogenetic Analysis of Virus Genomes
Full genomes of DENV strains isolated from treatment and placebo patients were analyzed for
each DENV type independently, along with DENV genomes originating from Asia that were
retrieved from NCBI GenBank. Multiple sequence alignments were performed using MAFFT
[33]. Maximum likelihood phylogenetic trees were constructed using RAxML applying the
General time reversible (GTR) model with gamma distributed rates across sites (GTR+γ) [34].
Trees were visualized and annotated using FigTree v1.5 (http://tree.bio.ed.ac.uk/software/
figtree/).
Table 2. Sequences of primers used to amplify the DENV1 and DENV2 genome in 6 overlapping fragments.
DENV1 Fragment Forward (5'-3') Reverse (5'-3') Region
1 AGTTGTTAGTCTACGTGGAC ACACCGCTGAACAAAACTCC 1–2084
2 TCACAAGAAGGAGCAATGCACA AAGAAGAACTTCTCTGGATGTTA 1697–3784
3 ACCAATGTTTGCTGTAGGGC TATTCCCCGTCTATTGCTGC 3727–6090
4 CAGAGCAACGCAGTTATCCA CAATTTAGCGGTTCCTCTCG 5501–7759
5 TCACAGATCCTCTTGATGCG CATGGCACCACTATTTCCCT 7364–9753
6 ATGGCTCACAGGAAACCAAC TGCCTGGAATGATGCTGTAG 8303–10690
DENV2 Fragment Forward (5'-3') Reverse (5'-3') Region
1 AGTWGTTAGTCTACGTGGAC TGGGCTGTCTTTTTCTGTGA 1–2028
2 GCAGAAACACAACATGGAACA AACGCGTCAGTCAGTTCAAG 1873–3857
3 GAAAGCTGACCTCCAAGGAA CTGAAATGTCTGTCGTGACCA 3578–5755
4 AGGCAGCTGGGATTTTCATGA TTTCCCTTCTGGTGTGACCA 5444–7797
5 ACTCAAGTATTGATGATGAGGA TGTGTCCAATCGTTCCATCCT 7360–9683
6 GCAGGATGGGACACAAGAAT AGAACCTGTTGATTCAACAG 9175–10703
doi:10.1371/journal.pntd.0004851.t002
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Results
Quantification of Viremia
All the 50 patients recruited to the study who tested positive on the Dengue Duo NS1 screening
kit and recruited to the study had virologically confirmed dengue [17] (Fig 1). On days 1, 2 and
3, there was strong and significantly positive correlation between viremia measured by qPCR
and the plaque assay (Fig 2A–2C) although by day 3, only 66% of the samples had positive vire-
mia by the plaque assay. By day 4, the correlation was weaker, but still significant (Fig 2D),
with only 34% of samples having positive viremia by the plaque assay compared to 98% by
qPCR. By day 5, only two samples were positive for dengue virus by plaque assay (Fig 2E).
There was no treatment effect when comparing the frequency of negative plaque assay results
for celgosivir and placebo groups. The kinetics of viral clearance (qPCR) was faster in second-
ary dengue than in primary dengue (Fig 3). VLR2-4 for patients with secondary dengue
(-2.25 ± 1.04) was significantly lower (p-value 0.002) than for those with primary dengue
(-1.46 ± 0.70); the difference (95% CI) was 0.79 (0.30, 1.29). On days 3 and 4, there were a sig-
nificantly higher number of negative plaque assays in secondary dengue patients compared to
primary dengue patients (Day 3: p-value<0.001, OR = 10.8, 95% CI 2.75 to 42.4; Day 4: p-
value = 0.029, OR = 5.79, 95% CI 1.13 to 29.6).
Pharmacokinetics
Celgosivir was rapidly converted to castanospermine in vivo, presumably by endogenous ester-
ases, as expected from previous animal and human studies [19]; 83% of the samples had no
quantifiable levels of parent drug above the lower limit of quantification. Observed mean casta-
nospermine Cmin and Cmax were 430 ng/mL (2.23 μM) and 5730 ng/mL (30.2 μM), respec-
tively (Table 2). Mean (± sd) oral clearance (CL/F) was 132 (± 28) mL/min. The mean volume
of distribution (V/F) was 28.2 (± 9.1) L, and half-life was 2.5 (± 0.6) hr. Using PK parameters
from compartmental modeling, the predicted mean plasma concentration profile during the
entire dosing period is shown in Fig 4. The data showed that the actual drug concentrations
remained above 400 ng/mL during the dosing period when mean viremia levels started from
greater than 6 logs and declined by more than 4 logs (Fig 3). The target concentration of 400
ng/mL was the trough concentration in mice treated with celgosivir using a dosing regimen (50
mg/kg bid for 5 days) that protected all animals from otherwise lethal dengue infection [22].
Body weight, age and sex were not significant covariates on clearance or volume of distribution
(Fig 5A–5D and 5F). On the other hand, castanospermine clearance and renal (creatinine)
clearance were significantly correlated (Fig 5E). Drug in the urine was>99% castanospermine,
and urinary recovery was 80% ± 17%.
Although only one dose was evaluated, a 3-fold range of exposure was obtained in observed
Cmin and a two-fold range in Cmax and predicted AUC (Table 3). There was a subtle trend
for lowered viremia (VLR2-4) with increasing Cmin (Fig 6) that was not evident with AUC.
This is in line with the concept of maintaining a serum concentration above a minimum inhibi-
tory concentration for optimizing antimicrobial/antiviral drug therapy. Although there was a
trend between VLR2-4 and quantiles of exposure of Cmin, and Cmax, neither one was signifi-
cantly correlated (Fig 6).
The PK parameters obtained from model fitting were used to predict Cmin, Cmax and
AUC for other dosing regimens (Fig 7). Simulations predicted that 150 mg given 8 hourly
(total daily dose of 450 mg) would increase steady-state Cmin by 2.4-fold, decrease steady-state
Cmax by 20% and increase daily AUC by only 13% compared to the regimen used in CELA-
DEN. Doses of 200 mg every 8 hr or 150 mg every 6 hr (total daily dose of 600 mg) would
Celgosivir PK/PD in Treatment of Dengue Fever
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Fig 2. Correlation between viremia by qPCR and plaque assay. Red filled circles–patients who received celgosivir;
blue open squares–patients who received placebo; lines–linear regression to all data. Pearson correlation coefficient for
all data (A)Day 1 0.79 (95% CI: 0.64 to 0.87); (B) Day 2 0.79 (95%CI: 0.65 to 0.87); (C) Day 3 0.83 (95% CI: 0.72 to 0.90);
(D) Day 4 (95%CI: 0.55 to 0.83); (E) Day 5 0.36 (95%CI: 0.08 to 0.58).
doi:10.1371/journal.pntd.0004851.g002
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achieve increases in steady-state Cmin by 3.2- and 4.5-fold, respectively with only a modest
33% increase in daily AUC.
Hematological, Immunomonitoring and NGS Analysis
The profiles for platelet count and hematocrit in the celgosivir and placebo groups are illus-
trated in Fig 8A and 8B. These show that the curves for the treatment and control groups are
Fig 3. Viremia kinetics in primary and secondary dengue patients. Log viremia Mean (± SEM) by day
and prior dengue infection status. Green solid circles connected by solid line–primary dengue; open orange
squares connected by dashed line–secondary dengue. Inset: VLR 2–4 by prior dengue infection status:
box 25th to 75th percentile, whiskers minimum and maximum values. Virus is cleared significantly faster in
secondary dengue compared to primary dengue (p = 0.002).
doi:10.1371/journal.pntd.0004851.g003
Fig 4. PK profile of castanospermine (semi-log plot). Solid brown line is the predicted concentration of
castanospermine based on the mean PK parameters and the dosing regimen studied in the trial. Gray open
circles are the observed peak and trough concentrations of castanospermine. Symbols and error bars are the
mean and SEM, respectively. Black dotted line is the target trough concentration (400 ng/mL) predicted
based on animal efficacy studies.
doi:10.1371/journal.pntd.0004851.g004
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Fig 5. Dependence of pharmacokinetic parameters on covariates. BodyWeight (A and B); Age (C and D); Creatinine
Clearance (E); and Sex (F). Clearance or volume of distribution were not significantly affected by patients’ body weight, age or sex.
Drug clearance was significantly correlated with creatinine clearance, indicating a significant role of the kidneys for elimination of
celgosvir. Solid line-linear regression, dashed line- 95% CI. The slope of the linear regression line of creatinine clearance versus
drug clearance was 0.86 (95%CI: 0.376, 1.351).
doi:10.1371/journal.pntd.0004851.g005
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almost exactly superimposed. However, because the celgosivir group had a much higher pro-
portion of secondary dengue (13/24 = 54%) than the placebo group (5/26 = 19%), and second-
ary dengue patients typically have a greater decrease in platelets and higher increase in
hematocrit (7, 8, 21 and 22), the comparable profiles are suggestive that celgosivir had some
benefit in secondary dengue. When only secondary dengue cases were compared, a trend
toward better outcomes in the celgosivir treated group is discernible (Fig 8C and 8D). Platelet
nadir and the difference between the maximum and minimum hematocrit for secondary den-
gue patients are shown in Fig 8E and 8F. The differences were not significant but are in the
direction of benefit for celgosivir. Due to the small numbers of patients in this subgroup, cau-
tion is warranted not to over-interpret these trends.
Numerous studies have demonstrated that the magnitude and quality of systemic immune
response during febrile dengue illness is linked to pathological disease progression. It has been
hypothesized that the expression of proinflammatory cytokines from innate and adaptive
immune effector cells plays a critical role in the cell activation, apoptosis, and vascular perme-
ability characteristics of dengue hemorrhagic fever [35, 36]. A comprehensive analysis of circu-
lating cytokines and chemokines was undertaken to assess the systemic impact of celgosivir
treatment on the immune status of acutely infected patients. Fig 9A shows the concentration of
circulating analytes at all time points for all patients in the trial. Longitudinal analysis of plasma
Table 3. Castanospermine PK parameters.
Cmin,obs Cmax,obs CL/F V/F K01 AUCss Tmax T1/2
ng/mL ng/mL mL/min L 1/hr ng/mL*hr hr hr
Mean 430 5727 131.8 28.2 4.48 26306 1.23 2.48
SD 116 1175 27.9 9.1 4.76 5154 0.77 0.57
Min 225 3970 92.6 15.3 0.4 16546 0.28 1.52
Median 412 5625 128.1 26.2 1.99 26017 1.21 2.71
Max 694 8500 201.5 49.9 14.94 35989 2.41 3.33
CV% 26.9 20.5 21.2 32.1 106.4 19.6 62.3 22.9
doi:10.1371/journal.pntd.0004851.t003
Fig 6. Scatterplots of drug exposure (Cmin, Cmax, AUC) and VLR2-4. Blue open squares–individual patients who received placebo; red filled
circles–individual patients who received celgosivir, separated into two quantiles of exposure. solid heavy line–median value, error bars– 25th to 75th
percentile.
doi:10.1371/journal.pntd.0004851.g006
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cytokine concentrations (Fig 9B) demonstrated that drug treatment led to a qualitative shift in
circulating cytokine and growth factor concentrations during the course of infection. Signifi-
cant increases in IL-13 and PDGF-AA concentrations were observed in celgosivir-treated pat-
ents relative to placebo-treated patients indicating an increase in Th2 polarizing cytokines with
time in this group. In support of this interpretation, drug treatment led to a corresponding
decrease in circulating levels of IFNγ and TGFα. This qualitative shift from a Th1 to Th2 pro-
file in patients receiving treatment may be reflective of a larger shift in T-cell polarization dur-
ing the course of treatment as observed in other antiviral treatments [37].
Due to the limited number of samples for DENV3, NGS analysis was performed only on
DENV1 and DENV2 isolates. Overall, our deep sequencing data shows positional variance
throughout the DENV genome for placebo and celgosivir-treated patients (S2 and S3 Figs).
Single nucleotide variants (SNVs) in each DENV population were called with the LoFreq vari-
ant calling algorithm. As in other studies [28,31], the majority (80% average across all samples)
of SNVs identified in our data set were transitions (S4 Fig). For both DENV1 and DENV2, the
bulk of the SNVs detected were present evenly in both treated and untreated populations, indi-
cating some level of non-specific selective pressure. However, significant difference in selection
pressure or genetic drift was observed between the different treatments for any of the viral
genes (S1 Table). Interestingly, the average SNV density for each dengue gene was lower for
celgosivir-treated patients compared to placebo-treated control (S2 Table).
No mutational hotspots were detected in any of the conditions for both DENV serotypes.
Consistent with a previous DENV1 study [32], cold-spots were detected in NS3 of DENV1
from placebo-treated samples (P-tp3). More cold-spots were also detected for celgosivir-treated
samples (C-tp1 and C-tp2) than placebo samples (P-tp1 and P-tp2) for DENV1 (S5A Fig). For
DENV2, coldspots were detected mostly in NS3 and NS5 for placebo-treated samples. For cel-
gosivir-treated samples, coldspots show a different profile from that of DENV1 and only exists
in the NS5 region (C-tp1 and C-tp3) (S5B Fig).
Phylogenetic Relationships of DENV Strains
Phylogenetic analysis of the whole genome sequences of treatment and placebo samples
revealed the co-circulation of multiple DENV lineages in our study (Fig 10). In particular, for
each DENV serotype, the treatment and placebo samples were derived from multiple geno-
types. Five independent lineages of DENV 2 were detected in this study, which belonged to two
major DENV 2 genotypes (Cosmopolitan and Asian). While the majority of DENV 2 samples
Fig 7. Predicted exposure for different dosing regimens. The Box-25th to 75th percentile, whiskers-minimum and maximum values for the
various dosing regimens is shown. (A) Cmin range for the various dosing regimens shows that 150 mg every 6 hr is predicted to yield a 4.5-fold
increase in median Cmin used in CELADEN trial (B) Cmax, range do not vary significantly for the various dosing regimens and (C) AUC only
shows a modest 1.33-fold increase over the dosing regimen used in the CELADEN trial.
doi:10.1371/journal.pntd.0004851.g007
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Fig 8. Changes in platelets and hematocrit for celgosivir (red filled circles) or placebo (blue open
squares) treated patients.Mean ± SEM changes in platelets count (A) and hematocrit (B) at different study
days in all patients. (C) and (D) are Mean ± SEM changes in platelets count (C) and hematocrit (D) at different
study days for secondary dengue patients only. Platelet nadir values (E) and difference between maximum
and minimum hematocrit values (F) for secondary dengue patients treated with celgosivir or placebo, solid
line–median, bars—interquartile range.
doi:10.1371/journal.pntd.0004851.g008
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Fig 9. Celgosivir treatment changes the systemic immune response during acute dengue infection. A) Scatter plot of cytokine
concentration of patient plasma samples drawn at specific time points post admission were analyzed for 41 cytokines and chemokines using
the Human cytokine panel 1. The standard for each analyte between 4–10000 pg/ml is presented as yellow dashes, quality control for each
analyte is in blue filled circles, a healthy volunteer (JEC) sample is shown in black filled circles the patient samples (400 samples/analyte; 8 per
Celgosivir PK/PD in Treatment of Dengue Fever
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were of the Cosmopolitan genotype we observed that they were derived from lineages that have
diverged many years ago, however both these lineages have been previously detected in Asia
during 2004–2012. Two lineages of DENV 1 and DENV 3 were also detected in our samples,
respectively, that belonged to different genotypes. Samples obtained from treatment and pla-
cebo patients were inter-dispersed among all lineages–represented by blue and red labeled
strains in each of the lineages, except in DENV 1 genotype IV and DENV 3 Genotype I where
only one sample type was detected (Fig 10). We were unable to assess the statistical significance
of sample type for each of the lineages due to small samples numbers among the lineages. How-
ever, these results suggest that the high genetic diversity of dengue may be a confounding factor
in the endpoint analysis of this drug trial. Currently, it is not known if the genetic changes prev-
alent between the different lineages would have an effect on the action of celgosivir, or related
anti-dengue drugs in early phase development such as UV-4, which also target ER alpha gluco-
sidases [38].
Discussion
Although CELADEN did not meet its primary endpoint of lowering viremia or fever, assess-
ment of the PK and pharmacodynamics provides valuable insights and lessons for the design
of future dengue drug trials, not only of celgosivir but of other dengue antivirals as well. An
important objective of early phase clinical trials is to identify dose regimen(s) that are safe and
tolerable and that show some evidence of pharmacological activity. Previous clinical experience
in hundreds of subjects (healthy volunteers, HIV and HCV patients) established that celgosi-
vir’s maximally tolerated dose (MTD) is 400 mg qd (once a day) for 12 weeks [20]. A small
trial in HCV patients (N = 43) reported asymptomatic, reversible increases in creatine kinase
(19% for 200 mg qd, 42% for 200 mg bid and 80% for 400 mg qd), suggesting that a divided
dose would be better tolerated than a single daily dose of the same amount of total drug [19].
Among CELADEN patients who received celgosivir, the mean observed trough castanosper-
mine concentration was 430 ng/mL (2.3 μM). This was comparable to the corresponding Cmin
in the mouse model (400 ng/mL) where 50 mg/kg bid for 5 days protected all animals from
dengue-related death when treated immediately after infection, and was far more effective than
100 mg/kg qd [22]. When treatment in mice was delayed by 24 and 48 hr post-infection, sur-
vival rates were lower at 75% and 50%, respectively [21]. In dengue patients, symptoms do not
arise until several days after infection. Therefore, it may be necessary to achieve higher trough
drug concentrations to overcome the delay in treatment after becoming infected. By decreasing
the dosing interval from 12 to 8 or 6 hr, PK simulations demonstrate that 2.4- to 4.5-fold
increase in Cmin are achievable with only a 13% to 33% increase in total dose. Indeed, AG129
mice treated at peak viremia with a four-times-daily regimen had a significantly reduced vire-
mia compared to untreated animals in a mouse viremia model using clinical isolates of DENV2
[23].
Drug clearance was significantly correlated with creatinine clearance, and 80% of the drug
was recovered in the urine, indicating that renal clearance is the dominant elimination path-
way, as was previously reported from animal studies [21]. While all patients in the trial had
serum creatinine levels well below the exclusion criterion of 165 μmol/l, retrospective creati-
nine clearance calculations indicated that one patient who had a serum creatinine of 114 μmol/
patient x 50 patients) are shown as green crosses. B) Heat map of log2 fold changes of averaged analyte concentrations at specific time points
against the pre-treatment concentrations for selected analytes showing qualitative shifts in the analyte concentrations. Treatment and control
groups fold changes are shown in separate rows for each analyte to aid comparison. Fold changes are colored from over expression in red to
under expression in green. A scale showing the value of the maximum and minimum log2 fold change is shown.
doi:10.1371/journal.pntd.0004851.g009
Celgosivir PK/PD in Treatment of Dengue Fever
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0004851 August 10, 2016 17 / 23
Fig 10. Evolutionary relationship of the whole genome of dengue samples isolated from celgosivir treatment and placebo in relation to
representative samples collected from Asia.Maximum likelihood trees were generated using the nucleotide alignment from start to stop codon of
the coding region. Tip labels are coloured based on sample type, and genotypes are labelled adjacent to tip labels for DENV 2, and along branches
for DENV 1 and 3. Scale bar represents nucleotide substitutions per site.
doi:10.1371/journal.pntd.0004851.g010
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fell in the moderate renal impairment category [39]. Although this issue did not specifically
result in any AE or SAE in CELADEN, our current PK analysis suggests a greater awareness of
renal function for future trials.
DENV cleared significantly more rapidly in patients with secondary dengue compared to
primary dengue, confirming a previous finding [40]. Future trials of antiviral drugs for dengue
drugs that use viremia as an endpoint may need to take this into account when calculating trial
size in order to achieve adequate power. Although an ideal case Target Product Profile [41]
for a dengue drug should be efficacy in both primary and secondary dengue, it is possible that
for some early phase proof-of-concept studies, previous infection status could either be an
inclusion criteria or a stratification variable to achieve balanced groups with respect to this
parameter.
In the clinical management of dengue, platelet count is closely monitored for signs of incipi-
ent bleeding and progression to more serious DHF. Hemoconcentration is monitored through
changes in hematocrit to decide whether to administer intravenous fluids and which type of
fluid should be given [42]. For Proof of Concept and early stage human clinical trials, it is
worth considering other parameters such as imaging leakage as an alternative early biomarker
for clinical outcome in assessing potential drugs to treat dengue fever [43]. By gathering evi-
dence to promote these biomarkers or hematology laboratory results to surrogate or valid clini-
cal endpoints, it will become easier to evaluate other dengue drugs in the future.
The NGS analysis to obtain critical information on nucleotide changes did not reveal any
suggestion that rapid development of resistance to celgosivir is an explanation for the low effi-
cacy observed in our trial. However it does reinforce the need for a panel of strains that are
representative for the various genotypes of DENV serotypes 1–4 to be examined as part of pre-
clinical evaluation for efficacy, especially when the drug targets a host enzyme. Interestingly
recent in vitro biochemical studies have confirmed that celgosivir’s mechanism of action is via
inhibition of ER α-gulcosidases and also showed that the antiviral activity of celgosivir in pri-
mary human macrophages in vitro, inhibits DENV secretion with an EC50 of 5 μM [44]. These
studies do lend support to celgosivir as a potential drug for detailed clinical analysis. Celgosi-
vir’s efficacy on zika virus (ZIKV) has not been reported but given its close relationship with
dengue virus within the flavivirus membership, it is possible that it may inhibit ZIKV using a
similar mechanism. ZIKV, like DENV is spread by Aedes aegypti mosquitoes but its current
association with widespread numbers of Guillain-Barre syndrome and microcephaly in babies
born to mothers infected during the first trimester of pregnancy is unique and a cause of much
concern [45].
Several lines of evidence suggest a trend towards a pharmacological effect of celgosivir in
dengue patients. Celgosivir patients with secondary dengue had a slightly less decline in plate-
lets. Only 1 of 13 (7.6%) of the secondary dengue patients treated with celgosivir had a platelet
nadir below 20,000/μL compared to 2 of 5 (40%) in the placebo group. Secondary dengue
patients treated with celgosivir also had a smaller difference between maximum and minimum
hematocrit than secondary dengue patients in the placebo group. Other evidence of a trend
towards pharmacologic activity include (i) the significantly lower level of TNFα in celgosivir-
treated patients compared to placebo controls during the early stage of treatment, independent
of prior infection status and (ii) enhanced NS1 clearance in secondary infection following cel-
gosivir treatment [17].
In conclusion, lessons derived from the analysis of the secondary endpoint data of the
CELADEN trial are a useful guide for future dengue drug trials. PK analyses and simulations
show that alternate dosing regimens can achieve several-fold increases in steady-state trough
concentrations with the same or modestly higher total dose. The difference in viremia kinetics
for primary and secondary dengue underscores the need for balanced arms with respect to
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infection status in future trials. Pathological endpoints such as HCT and vascular leakage may
be potentially better surrogate endpoints than viremia in assessing activity of dengue antivirals.
We note that CELADEN was not powered to determine statistically significant differences in
secondary endpoints. Such analyses are subject to inflated Type I error and merit cautious
interpretation. However taken together, the trends in pharmcological activity are consistent
with increasing celgosivir exposure. Since PK simulations of further divided doses suggest a
potentially large increase in Cmin with a modest increase in AUC, which is supported by recent
animal data [23], we plan to evaluate a revised dosing regimen of celgosivir in a Phase 2a to
start in 2016 (NCT02569827).
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